Učitavanje...
Targeted radionuclide therapies for pancreatic cancer
Pancreatic malignancies, the 4(th) leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a five-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radi...
Spremljeno u:
| Izdano u: | Cancer Gene Ther |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4826043/ https://ncbi.nlm.nih.gov/pubmed/26227823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cgt.2015.32 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|